Daiichi Sankyo, AstraZeneca and breast cancer

After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate could hit $5.9 billion in 2030. However, the asset faced a series of setbacks in 2024.
AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the closely watched treatment.
Daiichi Sankyo rises most in five months on cancer drug approval
Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a milestone in the company’s efforts to turn it into a widely used blockbuster. The stock climbed as much as 8% in early morning trading in Tokyo on Monday, the largest intraday gain since Aug. 6.
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer Drug
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday after rising as much as 9.7% earlier. Over the past three years, the stock posted a daily gain of more than 8% only four times.
AZ, Daiichi get FDA nod for Dato-DXd in breast cancer
The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast cancer, a few weeks after its first world approval in Japan.
Datroway, 2nd ADC from AstraZeneca-Daiichi collab, wins first FDA nod in breast cancer
Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the U.S. regulatory finish line. | AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate,
AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer
AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug Administration (FDA) to treat a subset of breast cancer patients.
STAT20h
A next-generation form of chemotherapy wins FDA approval
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
GlobalData on MSN7d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...
Pharm Exec1d
FDA Approves AstraZeneca, Daiichi Sankyo’s Datroway for Previously Untreated Unresectable, Metastatic HR-Positive, HER2-Negative Breast Cancer
Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...